Children’s Cancer Services

Debate between Lord Markham and Earl Russell

Wednesday 20th March 2024 Lords Chamber

[Lord Markham (Con)]

First, I thank my noble friend for the tireless work she does on behalf of the Royal Marsden, and convey the views of probably all noble Lords on the fantastic work the Royal Marsden does. The current situation, as I think noble Lords know, is that the NHS has reached a decision. The Secretary of State does have the power to call in exceptional cases, and as a result of that, Minister Stephenson is undertaking a fact-finding mission. I have set up a meeting with him to discuss this, and my noble friend is very welcome to join me at that meeting.

[Earl Russell (LD)]

My Lords, structural healthcare decisions are among the most challenging, and my worry is that there are greater risks now the Evelina has been chosen. It will be the only principal treatment centre in the UK where neurosurgery is not carried out on-site. St George’s has over 25 years’ experience in caring for children with cancer and a dedicated staff team of over 430 people, only four of whom will be moving to the Evelina. What actions will the Government be taking to monitor and ensure a continuing standard of cancer care for children?

[Lord Markham (Con)]

Ministers are on a fact-finding mission. I understand the points the noble Earl makes; the NHS made the point that it wants cancer treatment to be co-located alongside an intensive care unit. Following Professor Sir Mike Richards’ review, it believes that it is best to have those services co-located, which is why it has chosen the Evelina. There are pros and cons to every decision, and that is why Ministers are doing further fact-finding.

NHS: Drug Shortages

Debate between Lord Markham and Earl Russell

Wednesday 17th January 2024 Lords Chamber

[Lord Markham (Con)]

We find that each one is a different case in point. HRT is an example: we actually saw a 50% increase in demand for it over the last year, so suddenly that is quite a dislocation for the market, and you need to gear up very quickly in terms of the supply chain issues. Strep A was the example last year that we will all be familiar with; normally, it does not come until later in the year, but suddenly there was a very early outbreak in October, which caused the demand there. You find that every single drug tends to be a different case in point. There is a range of tools that they work with; it is working with the NHS, MHRA suppliers and pharmacists, and it is case by case. As I say, sometimes it is the MHRA expediting medicines to get new supply in; sometimes it is working on alternative suppliers; sometimes it is buying internationally—that is what we did in the case of strep A—and sometimes you do have to go as far as the serious shortage protocols, finding substitutes or, in extreme cases, changing doses. There is a range of programmes on it, which by and large are managing to tackle it.

[Earl Russell (LD)]

My Lords, can I ask the Minister specifically about the continued lack of supply of ADHD medication? The department said that the supply shortages would continue until April, when previously it had indicated that this supply issue would have been resolved by now. Do the Government understand the serious impacts that these shortages have, and the impact that the inability some people are facing to get any medication at all is having on their daily lives?

[Lord Markham (Con)]

There are 78 medicines for ADHD, 10 of which are particularly affected. We have put export restrictions in place on that, and we are working it through so that we can hopefully get it resolved by April. It is something we are working very closely on, because we know the importance.